Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $9.66 Average PT from Brokerages

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) have earned a consensus rating of “Hold” from the nine research firms that are presently covering the company, Marketbeat reports. Eight research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $9.66.

A number of equities analysts have commented on RVNC shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research note on Friday, November 8th. Guggenheim reaffirmed a “neutral” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. HC Wainwright reiterated a “neutral” rating and issued a $6.60 price objective on shares of Revance Therapeutics in a report on Friday, November 8th. Barclays reissued an “equal weight” rating and set a $7.00 target price (down previously from $10.00) on shares of Revance Therapeutics in a research note on Friday, September 13th. Finally, Stifel Nicolaus decreased their price target on Revance Therapeutics from $24.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, August 9th.

Revance Therapeutics Stock Performance

NASDAQ:RVNC opened at $4.31 on Tuesday. The stock has a 50 day moving average price of $5.50 and a 200 day moving average price of $4.43. The stock has a market cap of $452.12 million, a PE ratio of -2.24 and a beta of 0.95. Revance Therapeutics has a one year low of $2.30 and a one year high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The firm had revenue of $59.88 million during the quarter, compared to analyst estimates of $67.73 million. As a group, analysts predict that Revance Therapeutics will post -1.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Certuity LLC acquired a new position in Revance Therapeutics during the 2nd quarter worth about $26,000. FORA Capital LLC purchased a new stake in Revance Therapeutics during the third quarter worth about $54,000. Creative Planning acquired a new stake in shares of Revance Therapeutics during the third quarter worth about $56,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Revance Therapeutics during the second quarter worth about $33,000. Finally, Accredited Investors Inc. purchased a new position in shares of Revance Therapeutics in the third quarter valued at approximately $67,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.